Brokers Set Expectations for Cabaletta Bio FY2026 Earnings

Cabaletta Bio, Inc. (NASDAQ:CABA) – Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Cabaletta Bio in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn ($0.95) per share for the year. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share.

Cabaletta Bio (NASDAQ:CABA) last issued its earnings results on Wednesday, May 21st. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.04).

A number of other brokerages have also commented on CABA. Guggenheim upped their target price on Cabaletta Bio from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, May 15th. Citigroup dropped their price objective on Cabaletta Bio from $17.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, May 16th. Wells Fargo & Company dropped their price objective on Cabaletta Bio from $6.00 to $3.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 1st. UBS Group dropped their price objective on Cabaletta Bio from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Cabaletta Bio in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $20.33.

Cabaletta Bio Trading Up 2.9%

Shares of NASDAQ CABA opened at $1.80 on Wednesday. The business has a fifty day simple moving average of $1.53 and a 200 day simple moving average of $2.03. The firm has a market capitalization of $91.34 million, a price-to-earnings ratio of -0.84 and a beta of 2.81. Cabaletta Bio has a one year low of $0.99 and a one year high of $13.50.

Institutional Trading of Cabaletta Bio

Several large investors have recently made changes to their positions in the business. LPL Financial LLC grew its holdings in shares of Cabaletta Bio by 15.6% during the fourth quarter. LPL Financial LLC now owns 42,386 shares of the company’s stock worth $96,000 after purchasing an additional 5,716 shares during the last quarter. Intech Investment Management LLC grew its holdings in shares of Cabaletta Bio by 42.2% during the fourth quarter. Intech Investment Management LLC now owns 20,203 shares of the company’s stock worth $46,000 after purchasing an additional 5,999 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Cabaletta Bio by 23.3% during the fourth quarter. SG Americas Securities LLC now owns 43,259 shares of the company’s stock worth $98,000 after purchasing an additional 8,161 shares during the last quarter. Barclays PLC grew its holdings in shares of Cabaletta Bio by 17.2% during the fourth quarter. Barclays PLC now owns 71,617 shares of the company’s stock worth $163,000 after purchasing an additional 10,487 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Cabaletta Bio by 9.9% during the first quarter. Bank of New York Mellon Corp now owns 155,174 shares of the company’s stock worth $215,000 after purchasing an additional 14,026 shares during the last quarter.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.